1 | open-label | 6,357 |
2 | investigator-initiated | 167 |
3 | flexible-dose | 162 |
4 | assessor-blinded | 141 |
5 | open-labeled | 137 |
6 | observer-blinded | 132 |
7 | investigator-blinded | 94 |
8 | observer-blind | 81 |
9 | active-control | 78 |
10 | p.o. | 66 |
11 | event-driven | 49 |
12 | assessor-blind | 46 |
13 | evaluator-blinded | 42 |
14 | open-labelled | 36 |
15 | concentration-controlled | 34 |
16 | examiner-blind | 33 |
17 | investigator-blind | 33 |
18 | investigator-driven | 30 |
19 | irb-approved | 29 |
20 | astringent | 27 |
21 | tulsa | 27 |
22 | repeat-dose | 26 |
23 | diet-controlled | 24 |
24 | observer-masked | 24 |
25 | dose-optimization | 23 |
26 | randomized-withdrawal | 21 |
27 | highwire | 15 |
28 | evaluator-blind | 13 |
29 | 10-μg | 11 |
30 | forced-dose | 11 |
31 | ab/ba | 10 |
32 | dose-optimized | 10 |
33 | examiner-masked | 10 |
34 | monobactams | 10 |
35 | endoscopist-blinded | 9 |
36 | multiple-dosing | 9 |
37 | escalating-dose | 8 |
38 | investigator-led | 8 |
39 | one-period | 8 |
40 | open-trial | 8 |
41 | panther | 8 |
42 | rater-blind | 8 |
43 | assessor-masked | 7 |
44 | avaperl | 7 |
45 | fda-regulated | 7 |
46 | active-drug | 6 |
47 | cyclohexylamine | 6 |
48 | flexx | 6 |
49 | 46th | 5 |
50 | bu-shen-gu-chi-wan | 5 |
51 | j.c. | 5 |
52 | low-barrier | 5 |
53 | ncb®-df | 5 |
54 | nsc-45388 | 5 |
55 | open-phase | 5 |
56 | rhamnolipid | 5 |
57 | unflavoured | 5 |
58 | 84-week | 4 |
59 | anti-mutagenic | 4 |
60 | chemomodulatory | 4 |
61 | dtap-hib | 4 |
62 | enriched-enrollment | 4 |
63 | erato | 4 |
64 | hla-a*0201-restricted | 4 |
65 | incomplete-block | 4 |
66 | nimh-sponsored | 4 |
67 | open-treatment | 4 |
68 | placebo-free | 4 |
69 | treatment-withdrawal | 4 |
70 | 0.46-0.89 | 3 |
71 | 11-center | 3 |
72 | 24-gy | 3 |
73 | 8-12-week | 3 |
74 | 8-module | 3 |
75 | adair | 3 |
76 | archetypical | 3 |
77 | attachable | 3 |
78 | cws-96 | 3 |
79 | doca-salt+ranolazine | 3 |
80 | dyslipidemics | 3 |
81 | ethics-approved | 3 |
82 | ezetimibe- | 3 |
83 | ezetimibe-controlled | 3 |
84 | four-centre | 3 |
85 | freedom-c | 3 |
86 | hammering | 3 |
87 | individually-randomised | 3 |
88 | low-viscous | 3 |
89 | n-oh-2,6-dma | 3 |
90 | open-design | 3 |
91 | open-pericardium | 3 |
92 | operator-blinded | 3 |
93 | ortho-hydroxy | 3 |
94 | qhac8a | 3 |
95 | quilizumab | 3 |
96 | sensemaking | 3 |
97 | sham+ranolazine | 3 |
98 | sinkage | 3 |
99 | tipper | 3 |
100 | toyopearl | 3 |
101 | unarguably | 3 |
102 | δpepao | 3 |
103 | -04 | 2 |
104 | 11-study | 2 |
105 | 125- | 2 |
106 | 5683 | 2 |
107 | 6week | 2 |
108 | 7-arm | 2 |
109 | 8-month-long | 2 |
110 | abab/baba | 2 |
111 | adolescent-friendly | 2 |
112 | alk-1 | 2 |
113 | aluminum-adjuvated | 2 |
114 | analgesic-free | 2 |
115 | anbl0032 | 2 |
116 | anger/rage | 2 |
117 | annoy | 2 |
118 | antipoison | 2 |
119 | blind-observer | 2 |
120 | bridge-to-surgery | 2 |
121 | calor | 2 |
122 | casanova | 2 |
123 | coome | 2 |
124 | cupressuflavone | 2 |
125 | de-plan | 2 |
126 | digoxine | 2 |
127 | dual-institutional | 2 |
128 | e-consultation | 2 |
129 | envc | 2 |
130 | esi-tof-ms | 2 |
131 | ethnoherpetology | 2 |
132 | explorational | 2 |
133 | fecj | 2 |
134 | glu216 | 2 |
135 | h.s. | 2 |
136 | hdac7 | 2 |
137 | high-viscous | 2 |
138 | i50v | 2 |
139 | il-10- | 2 |
140 | imputation-based | 2 |
141 | intervention.four | 2 |
142 | kishimen | 2 |
143 | mechanical- | 2 |
144 | metotrexate | 2 |
145 | mmc/ft | 2 |
146 | mutpred | 2 |
147 | n-desmethylrosiglitazone | 2 |
148 | nci-h2052 | 2 |
149 | non-pmsg | 2 |
150 | nonadjuvant | 2 |
151 | open-extension | 2 |
152 | oral-to-sublingual | 2 |
153 | participant-friendly | 2 |
154 | pentoxifyline | 2 |
155 | pescovegetarian | 2 |
156 | rb- | 2 |
157 | review.for | 2 |
158 | scs-active | 2 |
159 | spion-gfap | 2 |
160 | still-experimental | 2 |
161 | taxus-i | 2 |
162 | taxus-v | 2 |
163 | tetramethyl- | 2 |
164 | ukpace | 2 |
165 | unquenched | 2 |
166 | variable-dosing | 2 |
167 | zutphen | 2 |
168 | α2-agonists | 2 |
169 | 'electro-convulsive | 1 |
170 | 1-week-off | 1 |
171 | 10,800-patient | 1 |
172 | 14-year-randomized | 1 |
173 | 2-surgical | 1 |
174 | 74-week | 1 |
175 | 83-d | 1 |
176 | 88-week | 1 |
177 | 89-d | 1 |
178 | aa-oriented | 1 |
179 | alkali-acid-heat | 1 |
180 | all-to-target | 1 |
181 | alpha-tocopherol/beta-carotene | 1 |
182 | alternating-tooth | 1 |
183 | aminoglycoside-ofx | 1 |
184 | analytic-descriptive | 1 |
185 | anti-wolbachial | 1 |
186 | antihypnozoite | 1 |
187 | antimineralization | 1 |
188 | apnp | 1 |
189 | cni/basiliximab | 1 |
190 | cognitive-respondent | 1 |
191 | cohort-expansion | 1 |
192 | cultureconsort | 1 |
193 | dam-assisted | 1 |
194 | depot-specific | 1 |
195 | diet-oriented | 1 |
196 | dose-frequency | 1 |
197 | dose-optimisation | 1 |
198 | drug-withdrawal | 1 |
199 | eight-cohort | 1 |
200 | elaspol | 1 |
201 | enriched-design | 1 |
202 | ethnoepidemiological | 1 |
203 | event-guided | 1 |
204 | experimental-type | 1 |
205 | experimenter-blind | 1 |
206 | explanatory/pilot | 1 |
207 | fertility/infertility | 1 |
208 | fortis-m | 1 |
209 | gelatine-kieselsol | 1 |
210 | gemfibrozil-lovastatin | 1 |
211 | gemofibrozil | 1 |
212 | heat-disrupted | 1 |
213 | hs-like | 1 |
214 | i..e. | 1 |
215 | immunoablative | 1 |
216 | inoculated-pack | 1 |
217 | interareal | 1 |
218 | l-racemate | 1 |
219 | la+rt- | 1 |
220 | laser-controlled | 1 |
221 | leave-out | 1 |
222 | lowering-pressure | 1 |
223 | measurements.one | 1 |
224 | methylprednisolone-valacyclovir | 1 |
225 | micromed | 1 |
226 | molecularly-directed | 1 |
227 | n-hydroxymethyl | 1 |
228 | neuro-scientific | 1 |
229 | nhs-funded | 1 |
230 | nonanxiolytic | 1 |
231 | noncarbapenem | 1 |
232 | nternational | 1 |
233 | omnatax | 1 |
234 | once-a-north | 1 |
235 | open/label | 1 |
236 | organo-manganese | 1 |
237 | outcome-research | 1 |
238 | phase-oriented | 1 |
239 | piperacillin- | 1 |
240 | placebo-controlled,24-week | 1 |
241 | placebo.probiotics | 1 |
242 | prime-only | 1 |
243 | pyrimethamine-sulphonamide | 1 |
244 | radiodine-131 | 1 |
245 | review.comparing | 1 |
246 | rituximab+bendamustine | 1 |
247 | rv-5h-nt3 | 1 |
248 | schema-therapy | 1 |
249 | scutari | 1 |
250 | sequential-dose | 1 |
251 | sertraline+tdcs | 1 |
252 | statims | 1 |
253 | subgroup-related | 1 |
254 | tetracycline/ | 1 |
255 | tt4-rule | 1 |
256 | ultramicrosize | 1 |
257 | urban-developed | 1 |
258 | urodynamical | 1 |
1 | 'electro-convulsive | 1 |
2 | -04 | 2 |
3 | 0.46-0.89 | 3 |
4 | 1-week-off | 1 |
5 | 10,800-patient | 1 |
6 | 10-μg | 11 |
7 | 11-center | 3 |
8 | 11-study | 2 |
9 | 125- | 2 |
10 | 14-year-randomized | 1 |
11 | 2-surgical | 1 |
12 | 24-gy | 3 |
13 | 46th | 5 |
14 | 5683 | 2 |
15 | 6week | 2 |
16 | 7-arm | 2 |
17 | 74-week | 1 |
18 | 8-12-week | 3 |
19 | 8-module | 3 |
20 | 8-month-long | 2 |
21 | 83-d | 1 |
22 | 84-week | 4 |
23 | 88-week | 1 |
24 | 89-d | 1 |
25 | aa-oriented | 1 |
26 | ab/ba | 10 |
27 | abab/baba | 2 |
28 | active-control | 78 |
29 | active-drug | 6 |
30 | adair | 3 |
31 | adolescent-friendly | 2 |
32 | alk-1 | 2 |
33 | alkali-acid-heat | 1 |
34 | all-to-target | 1 |
35 | alpha-tocopherol/beta-carotene | 1 |
36 | alternating-tooth | 1 |
37 | aluminum-adjuvated | 2 |
38 | aminoglycoside-ofx | 1 |
39 | analgesic-free | 2 |
40 | analytic-descriptive | 1 |
41 | anbl0032 | 2 |
42 | anger/rage | 2 |
43 | annoy | 2 |
44 | anti-mutagenic | 4 |
45 | anti-wolbachial | 1 |
46 | antihypnozoite | 1 |
47 | antimineralization | 1 |
48 | antipoison | 2 |
49 | apnp | 1 |
50 | archetypical | 3 |
51 | assessor-blind | 46 |
52 | assessor-blinded | 141 |
53 | assessor-masked | 7 |
54 | astringent | 27 |
55 | attachable | 3 |
56 | avaperl | 7 |
57 | blind-observer | 2 |
58 | bridge-to-surgery | 2 |
59 | bu-shen-gu-chi-wan | 5 |
60 | calor | 2 |
61 | casanova | 2 |
62 | chemomodulatory | 4 |
63 | cni/basiliximab | 1 |
64 | cognitive-respondent | 1 |
65 | cohort-expansion | 1 |
66 | concentration-controlled | 34 |
67 | coome | 2 |
68 | cultureconsort | 1 |
69 | cupressuflavone | 2 |
70 | cws-96 | 3 |
71 | cyclohexylamine | 6 |
72 | dam-assisted | 1 |
73 | de-plan | 2 |
74 | depot-specific | 1 |
75 | diet-controlled | 24 |
76 | diet-oriented | 1 |
77 | digoxine | 2 |
78 | doca-salt+ranolazine | 3 |
79 | dose-frequency | 1 |
80 | dose-optimisation | 1 |
81 | dose-optimization | 23 |
82 | dose-optimized | 10 |
83 | drug-withdrawal | 1 |
84 | dtap-hib | 4 |
85 | dual-institutional | 2 |
86 | dyslipidemics | 3 |
87 | e-consultation | 2 |
88 | eight-cohort | 1 |
89 | elaspol | 1 |
90 | endoscopist-blinded | 9 |
91 | enriched-design | 1 |
92 | enriched-enrollment | 4 |
93 | envc | 2 |
94 | erato | 4 |
95 | escalating-dose | 8 |
96 | esi-tof-ms | 2 |
97 | ethics-approved | 3 |
98 | ethnoepidemiological | 1 |
99 | ethnoherpetology | 2 |
100 | evaluator-blind | 13 |
101 | evaluator-blinded | 42 |
102 | event-driven | 49 |
103 | event-guided | 1 |
104 | examiner-blind | 33 |
105 | examiner-masked | 10 |
106 | experimental-type | 1 |
107 | experimenter-blind | 1 |
108 | explanatory/pilot | 1 |
109 | explorational | 2 |
110 | ezetimibe- | 3 |
111 | ezetimibe-controlled | 3 |
112 | fda-regulated | 7 |
113 | fecj | 2 |
114 | fertility/infertility | 1 |
115 | flexible-dose | 162 |
116 | flexx | 6 |
117 | forced-dose | 11 |
118 | fortis-m | 1 |
119 | four-centre | 3 |
120 | freedom-c | 3 |
121 | gelatine-kieselsol | 1 |
122 | gemfibrozil-lovastatin | 1 |
123 | gemofibrozil | 1 |
124 | glu216 | 2 |
125 | h.s. | 2 |
126 | hammering | 3 |
127 | hdac7 | 2 |
128 | heat-disrupted | 1 |
129 | high-viscous | 2 |
130 | highwire | 15 |
131 | hla-a*0201-restricted | 4 |
132 | hs-like | 1 |
133 | i..e. | 1 |
134 | i50v | 2 |
135 | il-10- | 2 |
136 | immunoablative | 1 |
137 | imputation-based | 2 |
138 | incomplete-block | 4 |
139 | individually-randomised | 3 |
140 | inoculated-pack | 1 |
141 | interareal | 1 |
142 | intervention.four | 2 |
143 | investigator-blind | 33 |
144 | investigator-blinded | 94 |
145 | investigator-driven | 30 |
146 | investigator-initiated | 167 |
147 | investigator-led | 8 |
148 | irb-approved | 29 |
149 | j.c. | 5 |
150 | kishimen | 2 |
151 | l-racemate | 1 |
152 | la+rt- | 1 |
153 | laser-controlled | 1 |
154 | leave-out | 1 |
155 | low-barrier | 5 |
156 | low-viscous | 3 |
157 | lowering-pressure | 1 |
158 | measurements.one | 1 |
159 | mechanical- | 2 |
160 | methylprednisolone-valacyclovir | 1 |
161 | metotrexate | 2 |
162 | micromed | 1 |
163 | mmc/ft | 2 |
164 | molecularly-directed | 1 |
165 | monobactams | 10 |
166 | multiple-dosing | 9 |
167 | mutpred | 2 |
168 | n-desmethylrosiglitazone | 2 |
169 | n-hydroxymethyl | 1 |
170 | n-oh-2,6-dma | 3 |
171 | ncb®-df | 5 |
172 | nci-h2052 | 2 |
173 | neuro-scientific | 1 |
174 | nhs-funded | 1 |
175 | nimh-sponsored | 4 |
176 | non-pmsg | 2 |
177 | nonadjuvant | 2 |
178 | nonanxiolytic | 1 |
179 | noncarbapenem | 1 |
180 | nsc-45388 | 5 |
181 | nternational | 1 |
182 | observer-blind | 81 |
183 | observer-blinded | 132 |
184 | observer-masked | 24 |
185 | omnatax | 1 |
186 | once-a-north | 1 |
187 | one-period | 8 |
188 | open-design | 3 |
189 | open-extension | 2 |
190 | open-label | 6,357 |
191 | open-labeled | 137 |
192 | open-labelled | 36 |
193 | open-pericardium | 3 |
194 | open-phase | 5 |
195 | open-treatment | 4 |
196 | open-trial | 8 |
197 | open/label | 1 |
198 | operator-blinded | 3 |
199 | oral-to-sublingual | 2 |
200 | organo-manganese | 1 |
201 | ortho-hydroxy | 3 |
202 | outcome-research | 1 |
203 | p.o. | 66 |
204 | panther | 8 |
205 | participant-friendly | 2 |
206 | pentoxifyline | 2 |
207 | pescovegetarian | 2 |
208 | phase-oriented | 1 |
209 | piperacillin- | 1 |
210 | placebo-controlled,24-week | 1 |
211 | placebo-free | 4 |
212 | placebo.probiotics | 1 |
213 | prime-only | 1 |
214 | pyrimethamine-sulphonamide | 1 |
215 | qhac8a | 3 |
216 | quilizumab | 3 |
217 | radiodine-131 | 1 |
218 | randomized-withdrawal | 21 |
219 | rater-blind | 8 |
220 | rb- | 2 |
221 | repeat-dose | 26 |
222 | review.comparing | 1 |
223 | review.for | 2 |
224 | rhamnolipid | 5 |
225 | rituximab+bendamustine | 1 |
226 | rv-5h-nt3 | 1 |
227 | schema-therapy | 1 |
228 | scs-active | 2 |
229 | scutari | 1 |
230 | sensemaking | 3 |
231 | sequential-dose | 1 |
232 | sertraline+tdcs | 1 |
233 | sham+ranolazine | 3 |
234 | sinkage | 3 |
235 | spion-gfap | 2 |
236 | statims | 1 |
237 | still-experimental | 2 |
238 | subgroup-related | 1 |
239 | taxus-i | 2 |
240 | taxus-v | 2 |
241 | tetracycline/ | 1 |
242 | tetramethyl- | 2 |
243 | tipper | 3 |
244 | toyopearl | 3 |
245 | treatment-withdrawal | 4 |
246 | tt4-rule | 1 |
247 | tulsa | 27 |
248 | ukpace | 2 |
249 | ultramicrosize | 1 |
250 | unarguably | 3 |
251 | unflavoured | 5 |
252 | unquenched | 2 |
253 | urban-developed | 1 |
254 | urodynamical | 1 |
255 | variable-dosing | 2 |
256 | zutphen | 2 |
257 | α2-agonists | 2 |
258 | δpepao | 3 |
1 | il-10- | 2 |
2 | 125- | 2 |
3 | rb- | 2 |
4 | ezetimibe- | 3 |
5 | mechanical- | 2 |
6 | tetramethyl- | 2 |
7 | piperacillin- | 1 |
8 | la+rt- | 1 |
9 | j.c. | 5 |
10 | i..e. | 1 |
11 | p.o. | 66 |
12 | h.s. | 2 |
13 | tetracycline/ | 1 |
14 | alk-1 | 2 |
15 | radiodine-131 | 1 |
16 | anbl0032 | 2 |
17 | nci-h2052 | 2 |
18 | 5683 | 2 |
19 | rv-5h-nt3 | 1 |
20 | -04 | 2 |
21 | glu216 | 2 |
22 | cws-96 | 3 |
23 | hdac7 | 2 |
24 | nsc-45388 | 5 |
25 | 0.46-0.89 | 3 |
26 | qhac8a | 3 |
27 | ab/ba | 10 |
28 | abab/baba | 2 |
29 | n-oh-2,6-dma | 3 |
30 | tulsa | 27 |
31 | casanova | 2 |
32 | cni/basiliximab | 1 |
33 | quilizumab | 3 |
34 | dtap-hib | 4 |
35 | freedom-c | 3 |
36 | depot-specific | 1 |
37 | neuro-scientific | 1 |
38 | anti-mutagenic | 4 |
39 | nonanxiolytic | 1 |
40 | envc | 2 |
41 | 83-d | 1 |
42 | 89-d | 1 |
43 | event-guided | 1 |
44 | observer-blinded | 132 |
45 | assessor-blinded | 141 |
46 | investigator-blinded | 94 |
47 | operator-blinded | 3 |
48 | evaluator-blinded | 42 |
49 | endoscopist-blinded | 9 |
50 | nhs-funded | 1 |
51 | unquenched | 2 |
52 | examiner-masked | 10 |
53 | observer-masked | 24 |
54 | assessor-masked | 7 |
55 | investigator-led | 8 |
56 | open-labeled | 137 |
57 | open-labelled | 36 |
58 | ezetimibe-controlled | 3 |
59 | concentration-controlled | 34 |
60 | laser-controlled | 1 |
61 | diet-controlled | 24 |
62 | micromed | 1 |
63 | urban-developed | 1 |
64 | nimh-sponsored | 4 |
65 | mutpred | 2 |
66 | unflavoured | 5 |
67 | imputation-based | 2 |
68 | individually-randomised | 3 |
69 | investigator-initiated | 167 |
70 | subgroup-related | 1 |
71 | fda-regulated | 7 |
72 | aluminum-adjuvated | 2 |
73 | molecularly-directed | 1 |
74 | hla-a*0201-restricted | 4 |
75 | aa-oriented | 1 |
76 | phase-oriented | 1 |
77 | diet-oriented | 1 |
78 | heat-disrupted | 1 |
79 | dam-assisted | 1 |
80 | irb-approved | 29 |
81 | ethics-approved | 3 |
82 | dose-optimized | 10 |
83 | 14-year-randomized | 1 |
84 | rhamnolipid | 5 |
85 | examiner-blind | 33 |
86 | rater-blind | 8 |
87 | experimenter-blind | 1 |
88 | observer-blind | 81 |
89 | assessor-blind | 46 |
90 | investigator-blind | 33 |
91 | evaluator-blind | 13 |
92 | one-period | 8 |
93 | ukpace | 2 |
94 | pyrimethamine-sulphonamide | 1 |
95 | analgesic-free | 2 |
96 | placebo-free | 4 |
97 | sinkage | 3 |
98 | anger/rage | 2 |
99 | hs-like | 1 |
100 | attachable | 3 |
101 | 8-module | 3 |
102 | tt4-rule | 1 |
103 | coome | 2 |
104 | alpha-tocopherol/beta-carotene | 1 |
105 | pentoxifyline | 2 |
106 | cyclohexylamine | 6 |
107 | rituximab+bendamustine | 1 |
108 | digoxine | 2 |
109 | sham+ranolazine | 3 |
110 | doca-salt+ranolazine | 3 |
111 | measurements.one | 1 |
112 | cupressuflavone | 2 |
113 | n-desmethylrosiglitazone | 2 |
114 | experimental-type | 1 |
115 | highwire | 15 |
116 | four-centre | 3 |
117 | lowering-pressure | 1 |
118 | open-phase | 5 |
119 | organo-manganese | 1 |
120 | forced-dose | 11 |
121 | flexible-dose | 162 |
122 | escalating-dose | 8 |
123 | sequential-dose | 1 |
124 | repeat-dose | 26 |
125 | l-racemate | 1 |
126 | metotrexate | 2 |
127 | antihypnozoite | 1 |
128 | 'electro-convulsive | 1 |
129 | immunoablative | 1 |
130 | scs-active | 2 |
131 | analytic-descriptive | 1 |
132 | ultramicrosize | 1 |
133 | ncb®-df | 5 |
134 | 1-week-off | 1 |
135 | sensemaking | 3 |
136 | review.comparing | 1 |
137 | hammering | 3 |
138 | variable-dosing | 2 |
139 | multiple-dosing | 9 |
140 | 8-month-long | 2 |
141 | non-pmsg | 2 |
142 | active-drug | 6 |
143 | 10-μg | 11 |
144 | outcome-research | 1 |
145 | 46th | 5 |
146 | alternating-tooth | 1 |
147 | once-a-north | 1 |
148 | taxus-i | 2 |
149 | scutari | 1 |
150 | fecj | 2 |
151 | inoculated-pack | 1 |
152 | incomplete-block | 4 |
153 | 8-12-week | 3 |
154 | placebo-controlled,24-week | 1 |
155 | 74-week | 1 |
156 | 84-week | 4 |
157 | 88-week | 1 |
158 | 6week | 2 |
159 | ethnoepidemiological | 1 |
160 | 2-surgical | 1 |
161 | urodynamical | 1 |
162 | archetypical | 3 |
163 | interareal | 1 |
164 | anti-wolbachial | 1 |
165 | open-trial | 8 |
166 | nternational | 1 |
167 | explorational | 2 |
168 | dual-institutional | 2 |
169 | still-experimental | 2 |
170 | oral-to-sublingual | 2 |
171 | randomized-withdrawal | 21 |
172 | drug-withdrawal | 1 |
173 | treatment-withdrawal | 4 |
174 | open-label | 6,357 |
175 | open/label | 1 |
176 | gemofibrozil | 1 |
177 | elaspol | 1 |
178 | active-control | 78 |
179 | gelatine-kieselsol | 1 |
180 | toyopearl | 3 |
181 | avaperl | 7 |
182 | n-hydroxymethyl | 1 |
183 | fortis-m | 1 |
184 | noncarbapenem | 1 |
185 | 7-arm | 2 |
186 | open-pericardium | 3 |
187 | pescovegetarian | 2 |
188 | de-plan | 2 |
189 | bu-shen-gu-chi-wan | 5 |
190 | zutphen | 2 |
191 | kishimen | 2 |
192 | investigator-driven | 30 |
193 | event-driven | 49 |
194 | enriched-design | 1 |
195 | open-design | 3 |
196 | gemfibrozil-lovastatin | 1 |
197 | cohort-expansion | 1 |
198 | open-extension | 2 |
199 | dose-optimisation | 1 |
200 | e-consultation | 2 |
201 | antimineralization | 1 |
202 | dose-optimization | 23 |
203 | antipoison | 2 |
204 | δpepao | 3 |
205 | erato | 4 |
206 | spion-gfap | 2 |
207 | apnp | 1 |
208 | panther | 8 |
209 | low-barrier | 5 |
210 | tipper | 3 |
211 | 11-center | 3 |
212 | blind-observer | 2 |
213 | adair | 3 |
214 | methylprednisolone-valacyclovir | 1 |
215 | review.for | 2 |
216 | calor | 2 |
217 | intervention.four | 2 |
218 | sertraline+tdcs | 1 |
219 | dyslipidemics | 3 |
220 | placebo.probiotics | 1 |
221 | esi-tof-ms | 2 |
222 | monobactams | 10 |
223 | statims | 1 |
224 | α2-agonists | 2 |
225 | high-viscous | 2 |
226 | low-viscous | 3 |
227 | alkali-acid-heat | 1 |
228 | all-to-target | 1 |
229 | mmc/ft | 2 |
230 | nonadjuvant | 2 |
231 | cognitive-respondent | 1 |
232 | astringent | 27 |
233 | 10,800-patient | 1 |
234 | enriched-enrollment | 4 |
235 | open-treatment | 4 |
236 | explanatory/pilot | 1 |
237 | eight-cohort | 1 |
238 | cultureconsort | 1 |
239 | leave-out | 1 |
240 | taxus-v | 2 |
241 | i50v | 2 |
242 | omnatax | 1 |
243 | aminoglycoside-ofx | 1 |
244 | flexx | 6 |
245 | dose-frequency | 1 |
246 | 11-study | 2 |
247 | 24-gy | 3 |
248 | ethnoherpetology | 2 |
249 | unarguably | 3 |
250 | participant-friendly | 2 |
251 | adolescent-friendly | 2 |
252 | prime-only | 1 |
253 | annoy | 2 |
254 | schema-therapy | 1 |
255 | bridge-to-surgery | 2 |
256 | chemomodulatory | 4 |
257 | fertility/infertility | 1 |
258 | ortho-hydroxy | 3 |